The enzyme replacement therapy market is poised to attain a valuation of US$ 9.3 billion in 2022, and it is projected to expand at a Compound Annual Growth Rate (CAGR) of 6.7%, reaching US$ 13.8 billion by the conclusion of 2028. Enzyme replacement therapy (ERT) revenue accounts for a substantial 63% share of the global hormone replacement market. The utilization of enzyme replacement therapy has been notably influenced by the increasing prevalence of rare disorders, and ongoing medical research is expected to accelerate this progress.
The growth in per capita healthcare expenditure in North America is forecasted to be a driving force behind market revenue expansion. Furthermore, the rapid advancement of healthcare infrastructure and heightened awareness campaigns in densely populated areas such as Asia Pacific and China are anticipated to play pivotal roles in bolstering revenue growth within the global enzyme replacement therapy market.
Discover the beauty of visuals in our complimentary report. @
https://www.futuremarketinsights.com/reports/sample/rep-gb-3167
Global Enzyme Replacement Therapy Market: Regional Insights
With nearly 25%-30% market share, North America dominated the global enzyme replacement therapy market in 2017, partly due to the presence of leading market players in the region. In developing regions such as Latin America, advancements in medical facilities are helping the region cope with healthcare crisis. Medical facilities in Brazil are equivalent with hospitals in the United States, with some even exceeding American standards. Brazil offers everything from large, full service hospitals to smaller, intimate private clinics.
Brazil has developed into a centre of excellence for healthcare in Latin America, with major universities that support research, teaching and training of medical professionals. Western Europe is the second largest market globally and is expected to be valued at US$ 2,893.2 Mn by 2028, with France, Italy and Spain projected to witness significant growth rates. Japan is expected to be the third largest market for enzyme replacement therapy.
Global Enzyme Replacement Therapy Markets: Segmentation & Forecast
The global enzyme replacement therapy markets has been segmented on the basis of therapeutic condition, route of administration, distribution channel and region. Therapeutic conditions in the enzyme replacement therapy markets include fabry disease, gaucher disease, mucopolysaccharidosis, pompe disease, lysosomal acid lipase deficiency and others.
Globally, the mucopolysaccharidosis therapeutic condition is the most attractive segment. Injectable segment remains the most lucrative route of administration in the enzyme replacement therapy markets. Among all distribution channels for enzyme replacement therapy, speciality treatment pharmacies are expected to be the most lucrative, followed by hospital pharmacies.
Key Research Findings
Enzyme replacement therapy is used in the treatment of rare diseases and the global market is projected to create incremental opportunity of US$ 6,448.3 Mn between 2022 and 2028
When compared to other established markets such as North America, the enzyme replacement therapy markets in Japan and Western Europe are expected to witness fast and steady growth, partly due to the increasing governmental support and growing demand for enzyme replacement therapy for the treatment of rare diseases.
Witness the transformation brought by our methodology insights today. @
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-3167
Global Enzyme Replacement Therapy Market: Competitive Landscape
- Sanofi S.A. (Genzyme Corporation)
- Shire plc.
- Pfizer Inc.
- Alexion Pharmaceuticals Inc.
- BioMarin Pharmaceutical Inc.
- Ultragenyx Pharmaceutical Inc.
- Johnson & Johnson Services Inc.
- Allergan plc.
- Leadiant Biosciences Inc.
Pompe Disease Treatment Market Is a type of treatment for certain genetic diseases that are caused by a deficiency in a specific enzyme. This therapy involves administering the missing enzyme to the patient, usually through intravenous infusion.
Key Segments of Enzyme Replacement Therapy Industry Survey
Enzyme Replacement Therapy Market by Therapeutic Condition:
- Enzyme Replacement Therapy for Fabry Disease
- Enzyme Replacement Therapy for Gaucher Disease
- Enzyme Replacement Therapy for Mucopolysaccharidosis
- MPS I
- MPS II (Hunter Syndrome)
- MPS IVA (Morquio Syndrome, Type A)
- MPS VI (Maroteaux-Lamy Syndrome)
- MPS VII (Sly Syndrome)
- Enzyme Replacement Therapy for Pompe Disease
- Enzyme Replacement Therapy for Lysosomal Acid Lipase Deficiency
- Others
Enzyme Replacement Therapy Market by Route of Administration:
- Oral Enzyme Replacement Therapy
- Injectable Enzyme Replacement Therapy
Enzyme Replacement Therapy Market by Distribution Channel:
- Hospital Pharmacies
- Specialty Treatment Pharmacies
- Retail Pharmacies
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube